Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study. Advani, R., Oki, Y., Shustov, A. R., Grove, L. E., Bartlett, N. AMER SOC CLINICAL ONCOLOGY. 2012
View details for Web of Science ID 000318009803855